There are 4 clinical trials

Clinical Trials

1 An Open-label Randomized Controlled Trial on Lopinavir/ Ritonavir, Ribavirin and Interferon Beta 1b Combination Versus Lopinavir/ Ritonavir Alone, as Treatment for 2019 Novel Coronavirus Infection

A combination of lopinavir/ ritonavir, ribavirin and interferon beta-1b will expedite the recovery, suppress the viral load, shorten hospitalisation and reduce mortality in patients with 2019-n-CoV infection compared with to lopinavir/ ritonavir

NCT04276688 Novel Coronavirus Infection Drug: Lopinavir/ritonavir Drug: Ribavirin Drug: Interferon Beta-1B

MeSH:Infection Coronavirus Infections Severe Acute Respiratory Syndrome

2 Sofosbuvir With and Without Ribavirin in Treatment of COVID 19 Patients

Sofosbuvir with and without ribavirin in treatment of COVID 19 Egyptian patients

NCT04460443 COVID Drug: sofosbuvir Drug: Ribavirin Drug: Daclatasvir

3 An Open-label Randomised Controlled Trial on IFN Beta-1b and Ribavirin Combination, as Treatment for Covid-19 Infection

As of 1 July 2020, more than 10 million people been confirmed to have infected by SARS-CoV-2, resulting in more than 500,000 deaths. No specific antiviral treatment for the SARS-CoV-2 is currently available, but existing medication could be repurposed. The investigators therefore propose to conduct an open-label randomized controlled trial on a short course of interferon β-1b and ribavirin combination treatment for patients hospitalized for COVID-19 infection.

NCT04494399 Covid19 Drug: Interferon beta-1b Drug: Ribavirin

4 Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients: A Randomized Controlled Trial.

efficacy and safety of Sofosbuvir containing regimens in treatment of COVID-19 Egyptian patients,

NCT04497649 Covid19 Drug: Sofosbuvir Drug: Daclatasvir Drug: Ribavirin Drug: Ledipasvir

No related HPO nodes (Using clinical trials)